Press Releases

Press Releases

Search by keywords:

180 Press Releases found

MRI Right Before or After Surgery Does Not Benefit Women with Early Breast Cancer

A Memorial Sloan Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates.

  • Wednesday, September 4, 2013

Memorial Sloan Kettering Cancer Center Unveils New Pressroom and Broadcast Studio

Memorial Sloan Kettering Cancer Center today unveiled a new pressroom for journalists with enhanced features as well as the availability of an on-site broadcast studio.

  • Tuesday, August 27, 2013

New Preferred Standard of Care for Advanced Kidney Cancer Patients

Patients with advanced kidney cancer can now take advantage of a new treatment option that has far fewer troubling side effects – this, according to a large, international trial led by Memorial Sloan Kettering Cancer Center investigators.

  • Wednesday, August 21, 2013

Study Suggests Pattern in Lung Cancer Pathology May Predict Cancer Recurrence after Surgery

A new study by thoracic surgeons and pathologists at Memorial Sloan Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence.

  • Wednesday, August 7, 2013

Most Popular Ovarian Cancer Cell Lines Do Not Resemble Ovarian Cancer

Researchers from Memorial Sloan Kettering Cancer Center recently discovered that the most frequently used cancer cell lines in ovarian cancer research are not suitable models of ovarian cancer.

  • Friday, July 12, 2013

Combination of Drugs Produces Dramatic Tumor Responses in Advanced Melanoma Patients

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published in The New England Journal of Medicine and presented at the 49th Annual Meeting of the American Society of Clinical Oncology.

  • Sunday, June 2, 2013

New Therapy Shown To Improve Progression-Free Survival and Shrink Tumors in Rare Cancer for the First Time

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology.

  • Saturday, June 1, 2013

Foundation Medicine and Memorial Sloan Kettering Cancer Center Announce Partnership to Advance Patient Care in Hematologic Cancers

Foundation Medicine and Memorial Sloan Kettering Cancer Center today announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers.

  • Thursday, May 2, 2013

Large Genomic Study Identifies Endometrial Cancer Subtypes, Treatment Opportunities

Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan Kettering Cancer Center and other centers within The Cancer Genome Atlas Research Network.

  • Wednesday, May 1, 2013

New Monoclonal Antibody Developed That Can Target Proteins Inside Cancer Cells

Scientists from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics have collaborated to create the new human monoclonal antibody, which targets a protein associated with many types of cancer and is of great interest to cancer researchers.

  • Wednesday, March 13, 2013